ClinicalTrials.gg
RecruitingNCT04475510HALTIUpdated Nov 4, 2026

Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke

An interventional study of Antiplatelet treatment discontinuation in Patent Foramen Ovale, Ischemic Stroke and Bleeding Ulcer, sponsored by Josep Rodes-Cabau. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Josep Rodes-Cabau · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.
Updated Nov 4, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Foramen Ovale, Patent with a site in Canada — 6 open to participants now, 9 under way, none of them phase 3. Foramen Ovale, Patent · Canada.

Started
2020
with 1 other
No phase
7 of 14
4 open now
Registered
7th of 14
by date
Lead sponsor
2 of 14
Josep Rodes-Cabau

Among the 14 studies in Foramen Ovale, Patent with a site in Canada, this one is one of 2 that started in 2020, is one of 7 with no phase, and was the 7th registered.

Foramen Ovale, Patent

137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.

Browse Foramen Ovale, Patent studies →

Open to participants now

6 of the 14 studies in Foramen Ovale, Patent with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Foramen Ovale, Patent with a site in Canada, or all of them as a file.
02

Study summary

To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.

Read the detailed description

Young patients with a cryptogenic ischemic event undergoing transcatheter PFO closure exhibit a low but clinically relevant risk of bleeding (overall and major bleeding) at long-term follow-up, eventually exceeding the risk of ischemic events.

Importantly, the vast majority of major bleeding events seem to occur in patients receiving antiplatelet therapy. Preliminary data suggest that antiplatelet therapy discontinuation is not associated with any increase in ischemic events, and could potentially translate into a lower rate of major bleeding events at longer term follow-up. We therefore hypothesize that in young patients without any other comorbidities increasing the risk of stroke, shorter-term (≤1 year instead of lifelong) antiplatelet treatment could be a safe option following PFO closure.

03

Conditions studied

  • Patent Foramen Ovale
  • Ischemic Stroke
  • Bleeding Ulcer

Keywords

  • Transcatheter Patent Foramen Ovale (PFO) closure
  • Ischemic Stroke
  • Bleeding
  • Young patients
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successful transcatheter PFO closure with any approved device
  • Patients ≤60 years diagnosed with a cryptogenic stroke/ who have undergone successful transcatheter PFO closure

Exclusion criteria

Exclusion Criteria:

->60 year-old

  • RoPE score \<6
  • Residual shunt ≥moderate following PFO closure
  • Atrial fibrillation following PFO closure
  • Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia)
  • Diabetes mellitus
  • Thrombophilia (factor V Leiden, factor II mutation, anticardiolipin antibodies, lupus anticoagulant, anti-b2 glycoprotein-I antibodies, protein C deficiency, protein S deficiency)
  • Recurrent cerebrovascular event (stroke, ) within the year following PFO closure
  • Failure to provide signed
  • Absolute for an MRI study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Antiplatelet treatment discontinuation

    At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.

    Other: Antiplatelet treatment discontinuation

Interventions

  • OtherAntiplatelet treatment discontinuation

    All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.

06

What researchers measure

Primary outcomes

  1. Presence of new stroke events

    1)Acute episode of a focal or global neurological deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax or other new neurological symptom(s) consistent with stroke.(2)Duration of a focal or global neurological deficit ≥ 24 hours OR \< 24 hours if available neuroimaging documents a new hemorrhage or infarct; OR the neurological deficit results in death.

    Time frame: 12 months

  2. Presence of new ischemic lesions

    Evaluated by MRI

    Time frame: 24-month follow-up

Secondary outcomes

  1. Number of new cerebral ischemic lesions

    Evaluated by MRI

    Time frame: 24-month follow-up

  2. Volume of new cerebral ischemic lesions

    Evaluated by MRI

    Time frame: 24-month follow-up

  3. Number of ischemic events

    Stroke, TIA

    Time frame: 24-month follow-up

  4. Number of ischemic events

    Stroke, TIA

    Time frame: 3-year follow-up

  5. Number of ischemic events

    Stroke, TIA

    Time frame: 4-year follow-up

  6. Number of ischemic events

    Stroke, TIA

    Time frame: 5-year follow-up

  7. Number of ischemic events

    Stroke, TIA

    Time frame: 6-year follow-up

  8. Number of ischemic events

    Stroke, TIA

    Time frame: 7-year follow-up

  9. Number of ischemic events

    Stroke, TIA

    Time frame: 8-year follow-up

  10. Number of ischemic events

    Stroke, TIA

    Time frame: 9-year follow-up

  11. Number of ischemic events

    Stroke, TIA

    Time frame: 10-year follow-up

  12. Rate of bleeding

    Life-threatening, major or minor bleeding

    Time frame: 24-month follow-up

  13. Rate of bleeding

    Life-threatening, major or minor bleeding

    Time frame: 3-year follow-up

  14. Rate of bleeding

    Life-threatening, major or minor bleeding

    Time frame: 4-year follow-up

  15. Rate of bleeding

    Life-threatening, major or minor bleeding

    Time frame: 5-year follow-up

  16. Rate of bleeding

    Life-threatening, major or minor bleeding

    Time frame: 6-year follow-up

  17. Rate of bleeding

    Life-threatening, major or minor bleeding

    Time frame: 7-year follow-up

  18. Rate of bleeding

    Life-threatening, major or minor bleeding

    Time frame: 8-year follow-up

  19. Rate of bleeding

    Life-threatening, major or minor bleeding

    Time frame: 9-year follow-up

  20. Rate of bleeding

    Life-threatening, major or minor bleeding

    Time frame: 10-year follow-up

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Jun 2027, 82 months after the start.

Of 31 interventional studies with no phase under Foramen Ovale, Patent, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 100. This study's planned 82 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jun 2027, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2020
First posted
Jul 17, 2020
StartActual
Jul 8, 2020
Primary completionEst.
Jun 1, 2027was Jun 2026
CompletionEst.
Aug 1, 2032
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 1, 2026→Jun 1, 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Jun 1, 2026→Jun 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04475510
Lead sponsor
Josep Rodes-Cabau
Responsible party
Josep Rodes-Cabau (Principal Investigator, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval) — Sponsor-investigator
First posted
Jul 17, 2020
Start date
Jul 8, 2020
Primary completion
Jun 1, 2027 (estimated)
Completion
Aug 1, 2032 (estimated)
Last update
Nov 4, 2026

Study contacts

Josep Rodes-Cabau, MD
Contact
josep.rodes@criucpq.ulaval.ca
4186568711
Melanie Cote, MSc
Contact
melanie.cote@criucpq.ulaval.ca
14186537270

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion